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Sub acute Sclerosing Pan Encephalitis (SSPE), a progressive neurological disorder 
characterized by inflammation of the brain (encephalitis), is the result of an 
inappropriate immune response to the measles virus or measles vaccination. 
SSPE usually develops 2 to 10 years after the original viral attack. Some of the 
major signs and symptoms are mental deterioration, jerky movements, and 
seizures specially myoclonic type, involuntary movements, and/or behavioral 
changes, difficulty in walking, speech, and loss of cognition, respiratory distress 
and death. 
Materials and Methods
During the ten years, from July 1991 to July 2001, we admitted 45 cases of 
(SSPE), at different stages of the disorder. Regardless of their stage of disease, 
for intervention, randomly, we used one of three drugs; Amantadin, Interferon 
alfa and Isoprinosine, administered to the patients, for between one month to 
one year. Fourteen cases received Amantadin, 15 Alfa interferon, and 16 were 
given Isoprinosine.
Results
While the results show all three drugs to be relatively effective, Isoprinosine 
showed four times more effectiveness than Amantadin and twice as much as 
Interferon.
Conclusion
The results showed Isoprinosine to be much more effective than Amantadin 
and Alfa interferon in treating the condition.
Keywords: Sub acute Sclerosing Panencephalitis, (SSPE), Dawson’s disease, 
Slow virus diseases.
Introduction
Sub acute Sclerosing Panencephalitis (SSPE) or Dawson’s disease is a rare disease of 
the slow virus infections group, with an onset between the ages of 7 to 10 years old 
approximately, presenting with a clinical picture of CNS degeneration (1).
On an average, the disorder begins 5 to10 years after a measles infection (2). The 
disorder displays relatively stereotyped clinical stages, as shown in Table1.
Alterations within the brain, usually evident on both, gross and microscopic 
examination (3), show sub acute encephalitis, accompanied by degeneration and 
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demylination; lesions generally involve the cerebral 
cortex, hippocampus, thalamus and brainstem (4) In the 
cerebral cortex, the histologic picture is a non-specific one 
in sub acute encephalitis with cell loss that is sometimes 
accompanied by neuronophagia and meningeal reaction 
and predominantly CD4+ T cells, whereas the parenchyma 
inflammatory infiltrations are B cells (5). Inclusions are 
seen within both the nucleus and the cytoplasm of neurons 
and eosinophilic material (Cowdry type A); less often, the 
inclusions are small and multiple (Cowdry type B) (6).The 
diagnosis of measles encephalitis can be established by 
detecting IgG titer elevations of measles virus in acute and 
convalescents serum or measles – specific IgM in serum 
or cerebrospinal fluid (7). The measles virus also can be 
detected in clinical samples using the reverse transcriptase 
polymerase chain reaction(8,9). MRI may reveal white 
matter lesions compatible with acute demylination, In 
SSPE, the cerebrospinal fluid, although usually normal 
may reveal a lymphocytosis and increase in measles 
antibodies (8). EEGs typically reveal myoclonic seizure 
or focal, generalized slowing or epileptiform discharges; 
CT is usually normal or shows atrophic changes, but an 
MRI can detect non-specific changes involving the cortex, 
white matter or deep nuclei (10). Paramyxovirus particles 
or measles virus RNA can be detected in brain tissue 
biopsy.
For treatment or to control disease progression, various 
kinds of drugs are used, such as steroids, Amantadin, α, 
β and γ interferon (11), transfer factor and Isoprinosine, 
each influencing at varying stages of the disease(12).
Materials and methods
Between July 1991 and 2001, 45 cases of SSPE, age range 
3-21 years old, were admitted in the children’s medical 
center; the mean age was 9 years old, with 32 males (71%) 
and 13 females (29%).
Patients were initially diagnosed based on clinical 
examination, and following that on the basis of the IgG 
titers of the serum and cerebrospinal fluid of patients; 
these antibody titers in the serum were between 1.64 to 
1.81 fold positive, mean 1.41; for CSF they were between 
1.4 to 1.102 fold positive, mean 1.51.
When initially examined at the first visit, the patients were 
at different stages of the disease process; based on clinical 
manifestations, stages were identified by a pediatric 
neurologist; table 1 shows the clinical manifestations.
Classification of disease stage
Clinical signs and symptoms and EEGs were used to 
classify disease stages of the patients as follows:
In stage one, mental regression and behavioral alteration 
(aggressiveness, depression, hallucination and cognitive 
disorders) are prominent; main signs and symptoms 
observed for those in stage two are jerky movements and 
myoclonic epilepsy, followed by difficulty in walking and 
talking. In stage three patients, 3 other forms of epilepsy 
as generalized tonic-clonic, partial and partial complex 
epilepsy, choreathetotic movements, disturbances of 
swallowing and speech were also observed, for which bed 
rest was advised for affected patients. Severe mental and 
motor deterioration, full defect in cognition, disturbances 
in urination and defecation and progressive respiratory 
infection, possibly fatal, were features observed in stage 
four patients (Table1).
Based on EEGs, done for all patients, of 24 cases in stages 
one and two, results of 15 showed typically myoclonic 
epilepsy, while the results of one patient demonstrated 
slowing and partial, or partial complex epilepsy; EEGs of 
the remaining patients, in stages three and four, showed 
severe slowing and partial epilepsy.
Twenty cases had brain CT, half of whom were in stages 1 
and 2, had mild to moderate brain atrophy and the other ten 
cases showed brain atrophy with gliosis and demylinating 
process (fig1).
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Table 1:Clinical Differentiation of SSPE in different stages.
Stage 1 Stage 2 Stage 3 Stage 4 
Mental deterioration
Psychomotor regression











Reduction in Myoclonic 
seizures
Unable to walk
Other kinds of seizure















Of patients with stage one disease, 3 patients were given 
Amantadin, while 3 other cases received α-INF and 4 
other patients took Isoprinosine; among those classified 
as second stage, 4 patients received Amantadin and 5 
patients were administered with α-INF and Isoprinosine 
respectively. Stage three patients were treated with 
5 patients in each group received Amantadin, Alfa 
interferon and Isoprinsine. Those patients with stage four 
of the disease were treated as follows: Amantadin with 
oral administration 10-15 mg/kg for 3 to 6 months, α-
INF subcutaneously 3-6 million units, three times weekly 
for 3 months and Isoprinosine (Inosine pranobex) 100 
mg/kg/day for 6 months. We followed up all patients 
every 2-3 months by neurological examination, EEG 
and psychometric tests. Patients whose follow-ups were 
incomplete were contacted by phone.
Definition of drugs effectiveness
Three levels of drug effectiveness were used:
1. Complete stop/cessation: Remaining at the same stage 
for long time after treatment or no progression to next 
stage of disease for at least one year or more. 
2. Slow progression: This was when the progression of 
disease from one stage to another, lasted over two years 
following treatment.
3. Non-effective: If no change was observed in progression 
and/or deterioration in the signs and symptoms occurred, 
the drug was considered to be non effective.
Results
In our study, we randomly administered one of the 
three drugs, Amantadin, Alfa Interferon or Isoprinosine 
for treatment of 45 patients suffering from sub acute 
sclerosing panencephalits, at different stages.
Of 14 cases treated with Amantadin, in one patient 
(7/15%), full cessation or “stop” of disease was seen. 
Three (21/5%), had slowed progression and in 10 (71/5%) 
cases, treatment was non effective.
In 15 cases that received subcutaneous Interferon alfa, 
2 (13/33%) had complete stop of disease progression, 5 
cases (33/33%), had slowed progression and in 8 patients 
(53/33%), the treatment was non-effective. 
Of the 16 patients receiving Isoprinosine, in 4 (25%), 
disease progression stopped, 6 (37/5%) exhibited slow 
progression, and in 6 other patients (37/5%), the drug had 
no effect or was non-effective.
Six patients showed no response to drug treatment; two of 
these died within a year of admission, three of them died 
within two years, and the third lived for over two years. 
Of the 3 cases that showed slowed progress with 
Amantadin, 2 lived for between two to three years, while 
the third survived for over 3 years.
From among 5 patients that had slow progression 
following Interferon alfa therapy, two died between 2 to 3 
years after admission, whereas 3 lived for between 3 to 5 
years following hospitalization.
Of six patients that had slow disease progression, using 
Isoprinosine, 3 lived for up to 4 years after admission, 
2 for up to 7 years, while one lived for ten years after 
treatment (Table 2).
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While the results show all three drugs to be relatively effective, Isoprinosine showed four times more effectiveness than 
Amantadin and twice as much as Interferon (Fig 2). 
Table 2:The effects of drugs used in our patients





Slowed progression in 1 case
Non affective in 4 cases
4cases:
Slowed progression in 1 case
Non affective in 3 cases
3cases:
Complete stop in one case
Slowed progression in 1 case





Slow progression in 1case
Non effective in 4 cases
5cases:
Complete stop in 1 case
Slowed progression in 2 case
Non affective in 2 cases
3cases:
Complete stop in 1 case
Slow progression in 1 case






Slowed progression in 3 cases
Non effect in 2 cases
5cases:
Complete stop in 2 cases
Slowed progression in 2 cases
Non effect in 1 case
4cases:
Complete stop in 2 case
Slowed progression in 1 case
Non effect in one case
Isoprinosin
Discussion
 Sub acute sclerosing panencephlitis is a degenerative disease that caused by measles virus that initially produces an acute 
measles infection or immunization after routine vaccination (13). The measles virus normally has 7 kinds of protein that 
body produce specific antibodies against that proteins; however in some patients there is defective antibody production for 
the M particle of the measles protein that influences virus invasion of the cells and the brain and prodiuoce destruction of 
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deterioration of the functioning of the cortex, sub cortical 
tissues, spongy degeneration in cortico- sub cortical 
regions, cerebellum and the brainstem may be seen(14). 
This process is accompanied by increases of the measles 
antibody in the CSF and the patient’s blood, as seen in our 
patients(15).
Various kinds of drugs are used to control disease 
progression and some of these can have temporary side-
effects (10). In this study we found out that the best result 
is obtained using Isoprinosine in comparison to the other 
drugs investigated; the mean survival rate of 6 years 
was documented for Isoprinosine users, in comparison 
with 4 and 3.33 years for those administered α-INF and 
Amantadin respectively. A 1997 study showed that, in 
patients treated with intra ventricular α-INF and oral 
Inosiplex, the survival was between 9 to 54 months (mean 
2.83 years); although the effect of α-INF is limited, they 
found it to be most efficient therapeutic agent in treatment 
of SSPE (10). In another study, a case report, the patient 
after combination of α-INF, Ribavirin and Inosiplex 
therapy improved between 6 months to 10 months, but 
then his condition suddenly deteriorated and he died (15). 
However in our study we demonstrated that complete stop 
(25%) and slow progression (37.5%) were found in the 
Isoprinosine group.
Because of the limited numbers of patients, the statistical 
test did not show any significant differences between our 
three groups (p-value>0.05), but the results can definitely 
show the efficacy of Isoprinosine, on disease progression 
and patient survival, in comparison with two other drugs.
Anlar and Coworkers recommend intraventricular 
Interferon and oral Isoprinosine, especially for those with 
slow progressive disease; this can produce longer life 
expectancy (16).
A multi national trial indicated that approximately 35% 
of patients with SSPE stabilize during Inosine pronabex, 
whereas they had no added benefit from interferon alfa 
(17)Some patients have improved or stabilized after 
several 6-week of treatment with interaventriculr alpha 
interferon, starting at 105 inosine probex (Isoprinosine), 
100mg/kg/day, courses which can be repeated six times at 
2 to 6 month intervals(18).
Clonazepam, sodium valproate and some time 
cabamazpine are effective in controlling myoclonic jerks 
and other type of seizures (19).
Conclusion
Although all three drugs were found to be relatively 
effective, Isoprinosine showed four times more 
effectiveness than Amantadin and twice as much as 
Interferon.
Because of the chronic and progressive nature of SSPE 
and similarity of clinical manifestations after treatment 
with spontaneous remissions, further long term studies are 
strongly recommended to investigate drug effectiveness 
for the appropriate treatment this disease
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